Please Wait.....
Report
Asia-Pacific Stroke Market
Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research
The Asia-Pacific stroke market is expected to reach USD 13.71 billion by 2032 from USD 7.01 billion in 2024, growing at a substantial CAGR of 9.1% in the forecast period of 2025 to 2032.
Market Segmentation:
Asia-Pacific Stroke Market, By Type (Ischemic Stroke, Hemorrhage Stroke, and Transient Ischemic Attack (TIA)), Diagnosis & Treatment (Treatment and Diagnosis), Gender (Female and Male), End User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories, and Others), Distribution Channel (Direct, Retail, and Online), Country (Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Taiwan, and rest of Asia-Pacific) - Industry Trends & Forecast To 2032
Overview of the Asia-Pacific Stroke Market Dynamics:
Drivers
- Rising incidences of stroke drive demand for treatments
- Increasing number of patients with hypertension and coronary heart diseases
Restraints
- High cost of diagnosis
- Increase in product recalls
Opportunities
- High cost of diagnosis
- Increase in product recalls
Market Players:
The key market players for Asia-Pacific stroke market are listed below:
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd
- DAIICHI SANKYO COMPANY, LIMITED
- Sanofi
- Johnson & Johnson Services, Inc.
- Bayer AG
- Sandoz AG
- Pfizer Inc.
- Medtronic
- Abbott
- Viatris Inc.
- AstraZeneca
- Penumbra, Inc.
- GLENMARK PHARMACEUTICALS LTD
- Fresenius SE & Co. KGaA
- Teva Pharmaceuticals USA, Inc.
- Lupin
- Amneal Pharmaceuticals LLC
TABLE OF CONTENTS
1 INTRODUCTION 76
1.1 OBJECTIVES OF THE STUDY 76
1.2 MARKET DEFINITION 76
1.3 LIMITATIONS 78
1.4 MARKETS COVERED 78
2 MARKET SEGMENTATION 83
2.1 MARKETS COVERED 83
2.2 GEOGRAPHICAL SCOPE 84
2.3 YEARS CONSIDERED FOR THE STUDY 85
2.4 CURRENCY AND PRICING 85
2.5 DBMR TRIPOD DATA VALIDATION MODEL 86
2.6 MULTIVARIATE MODELLING 89
2.7 TYPE LIFELINE CURVE 89
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 90
2.9 DBMR MARKET POSITION GRID 91
2.10 MARKET END USER COVERAGE GRID 92
2.11 VENDOR SHARE ANALYSIS 93
2.12 SECONDARY SOURCES 94
2.13 ASSUMPTIONS 94
3 EXECUTIVE SUMMARY 95
4 PREMIUM INSIGHTS 97
4.1 PESTEL ANALYSIS 100
4.2 PORTER'S FIVE FORCES 101
5 ASIA-PACIFIC STROKE MARKET, REGULATORY FRAMEWORK 102
5.1 REGULATION IN U.S. 102
5.2 REGULATION IN EUROPE 103
5.3 REGULATION IN CHINA 104
5.4 REGULATION IN JAPAN 104
5.5 REGULATION IN SOUTH AFRICA 105
6 MARKET OVERVIEW 106
6.1 DRIVERS 108
6.1.1 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS 108
6.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES 109
6.1.3 INCREASING DIABETIC AND OBESE POPULATIONS ELEVATE STROKE RISKS 110
6.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY IMPROVE STROKE CARE OUTCO.MES 110
6.2 RESTRAINTS 112
6.2.1 HIGH COST OF DIAGNOSIS 112
6.2.2 INCREASE IN PRODUCT RECALL 112
6.3 OPPORTUNITIES 114
6.3.1 DEVELOPMENT OF ADVANCED THERAPEUTICS FOR STROKES 114
6.3.2 EXPANSION IN STROKE REHABILITATION SERVICES 114
6.3.3 INNOVATIVE TREATMENTS IN PIPELINE FOR STROKE TREATMENT 115
6.4 CHALLENGES 116
6.4.1 FALSE DIAGNOSIS IN STROKES 116
6.4.2 COMPLICATIONS ASSOCIATED WITH MANAGING STROKE 117
7 ASIA-PACIFIC STROKE MARKET, BY TYPE 118
7.1 OVERVIEW 119
7.2 ISCHEMIC STROKE 122
7.2.1 THROMBOTIC (CEREBRAL THROMBOSIS) 123
7.2.2 EMBOLIC (CEREBRAL EMBOLISM) 123
7.3 HEMORRHAGIC STROKE 124
7.3.1 SUBARACHNOID HEMORRHAGE 124
7.3.2 INTRACEREBRAL HEMORRHAGE 124
7.4 TRANSIENT ISCHEMIC ATTACT (TIA) 125
8 ASIA-PACIFIC STROKE MARKET, BY GENDER 126
8.1 OVERVIEW 127
8.2 FEMALE 130
8.3 MALE 131
9 ASIA-PACIFIC STROKE MARKET, BY DIAGNOSIS AND TREATMENT 132
9.1 OVERVIEW 133
9.2 TREATMENT 136
9.2.1 BY TREATMENT TYPE 137
9.2.1.1 MEDICATION 137
9.2.1.1.1 MEDICATION, BY CLASS 137
9.2.1.1.1.1 BLOOD PRESSURE MEDICINES 138
9.2.1.1.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 139
9.2.1.1.1.1.2 RAMIPRIL 139
9.2.1.1.1.1.3 LISINOPRIL 139
9.2.1.1.1.1.4 ENALAPRIL 139
9.2.1.1.1.1.5 PERINDOPRIL 139
9.2.1.1.1.1.6 OTHER 139
9.2.1.1.1.2 THIAZIDE DIURETICS 140
9.2.1.1.1.2.1 INDAPAMIDE 140
9.2.1.1.1.2.2 BENDROFLUMETHIAZIDE 140
9.2.1.1.1.2.3 SPIRONOLACTONE 140
9.2.1.1.1.2.4 AMILORIDE 140
9.2.1.1.1.2.5 OTHER 140
9.2.1.1.1.3 CALCIUM CHANNEL BLOCKERS 141
9.2.1.1.1.3.1 AMLODIPINE 141
9.2.1.1.1.3.2 NIFEDIPINE 141
9.2.1.1.1.3.3 VERAPAMIL 141
9.2.1.1.1.3.4 NICARDIPINE 141
9.2.1.1.1.3.5 FELODIPINE 141
9.2.1.1.1.3.6 NIMODIPINE 141
9.2.1.1.1.3.7 OTHERS 141
9.2.1.1.1.4 BETA BLOCKERS 142
9.2.1.1.1.4.1 ATENOLOL 142
9.2.1.1.1.4.2 BISOPROLOL 142
9.2.1.1.1.4.3 LABETOLOL 142
9.2.1.1.1.4.4 OTHERS 142
9.2.1.1.1.5 ALPHA-BLOCKERS 143
9.2.1.1.1.5.1 DOXAZOSIN 143
9.2.1.1.1.5.2 OTHERS 143
9.2.1.1.1.6 OTHERS 143
9.2.1.1.1.7 ANTIPLATELET DRUGS 144
9.2.1.1.1.7.1 ASPIRIN 144
9.2.1.1.1.7.2 CLOPIDOGREL 144
9.2.1.1.1.7.3 DIPYRIDAMOLE 144
9.2.1.1.1.7.4 TICLOPIDINE 144
9.2.1.1.1.7.5 OTHERS 144
9.2.1.1.1.8 ANTICOAGULANTS 145
9.2.1.1.1.8.1 WARFARIN 145
9.2.1.1.1.8.2 APIXABAN 145
9.2.1.1.1.8.3 DABIGATRAN 145
9.2.1.1.1.8.4 HEPARIN 145
9.2.1.1.1.8.5 RIVAROXABAN 145
9.2.1.1.1.8.6 OTHERS 145
9.2.1.1.1.9 TISSUE PLASMINOGEN ACTIVATOR (TPA) 146
9.2.1.1.1.9.1 ALTEPLASE 146
9.2.1.1.1.9.2 TENECTEPLASE 146
9.2.1.1.1.9.3 RETEPLASE 146
9.2.1.1.1.9.4 ANISTREPLASE 146
9.2.1.1.1.9.5 OTHERS 146
9.2.1.1.1.10 STATINS 147
9.2.1.1.1.10.1.1 ATORVASTATIN 148
9.2.1.1.1.10.1.2 SIMVASTATIN 148
9.2.1.1.1.10.1.3 LOVASTATIN 148
9.2.1.1.1.10.1.4 ROSUVASTATIN 148
9.2.1.1.1.10.1.5 FLUVASTATIN 148
9.2.1.1.1.10.1.6 PRAVASTATIN 148
9.2.1.1.1.10.1.7 PITAVASTATIN 148
9.2.1.1.1.10.1.8 OTHERS 148
9.2.1.1.1.11 VITAMIN K 149
9.2.1.1.1.12 SUPPORTIVE MEDICATION 149
9.2.1.1.1.12.1 NUTRITIONAL SUPPLEMENTS 149
9.2.1.1.1.12.2 ANTIPYRETICS 149
9.2.1.1.1.12.3 OTHERS 149
9.2.1.1.2 MEDICATION, BY DRUG TYPE 150
9.2.1.1.2.1 BRANDED 150
9.2.1.1.2.1.1 ACTIVASE 151
9.2.1.1.2.1.2 EDOBAXAN 151
9.2.1.1.2.1.3 COUMADIN 151
9.2.1.1.2.1.4 HEPARIN LEO 151
9.2.1.1.2.1.5 DUOPLAVIN 151
9.2.1.1.2.1.6 AGGRENOX 151
9.2.1.1.2.1.7 RETAVASE 151
9.2.1.1.2.1.8 JANTOVEN 151
9.2.1.1.2.1.9 CATHFLO 151
9.2.1.1.2.1.10 OTHER 151
9.2.1.1.2.2 GENERIC 151
9.2.1.1.3 MEDICATION, BY ROUTE OF ADMINISTRATION 152
9.2.1.1.3.1 ORAL 152
9.2.1.1.3.1.1 TABLET 152
9.2.1.1.3.1.2 CAPSULES 152
9.2.1.1.3.1.3 OTHERS 152
9.2.1.1.3.2 PARENTERAL 153
9.2.1.1.3.2.1 INTRAVENOUS 153
9.2.1.1.3.2.2 SUBCUTANEOUS 153
9.2.1.1.3.3 OTHERS 153
9.2.1.1.4 MEDICATION, BY MODE OF PURCHASE 154
9.2.1.1.4.1 PRESCRIPTION 154
9.2.1.1.4.2 OVER THE COUNTER (OTC) 154
9.2.1.1.5 MEDICATION, BY THERAPY TYPE 154
9.2.1.1.5.1 COMBINATION THERAPY 154
9.2.1.1.5.2 MONOTHERAPY 154
9.2.1.2 SURGERY 155
9.2.1.2.1 EMBOLIC COILS 155
9.2.1.2.2 ASPIRATION CATHETERS 155
9.2.1.2.3 STENT RETRIEVER 155
9.2.1.2.4 SURGICAL CLIPPING 155
9.2.1.2.5 OTHERS 155
9.2.1.3 OTHERS THERAPY 156
9.2.1.3.1 PHYSICAL THERAPY 156
9.2.1.3.2 OCCUPATIONAL THERAPY 156
9.2.1.3.3 SPEECH THERAPY 156
9.2.1.3.4 OTHERS 156
9.3 DIAGNOSIS 157
9.3.1 IMAGING TEST 158
9.3.1.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN 158
9.3.1.2 MAGNETIC RESONANCE IMAGING (MRI) 158
9.3.1.3 CAROTID ULTRASOUND 158
9.3.1.4 CEREBRAL ANGIOGRAM 158
9.3.2 BLOOD TEST 158
9.3.3 ECHOCARDIOGRAM 158
9.3.4 LUMBAR PUNCTURE 158
9.3.5 OTHERS 158
10 ASIA-PACIFIC STROKE MARKET, BY DISTRIBUTION CHANNEL 159
10.1 OVERVIEW 160
10.2 DIRECT 163
10.3 RETAIL 164
10.4 ONLINE 164
11 ASIA-PACIFIC STROKE MARKET, BY END USER 165
11.1 OVERVIEW 166
11.2 HOSPITALS & CLINICS 169
11.3 SPECIALTY CLINICS 170
11.4 AMBULATORY SURGICAL CENTER 170
11.5 HOMECARE 171
11.6 LABORATORIES 171
11.7 OTHERS 172
12 ASIA-PACIFIC STROKE MARKET, BY REGION 173
12.1 ASIA-PACIFIC 175
12.1.1 CHINA 187
12.1.2 JAPAN 198
12.1.3 INDIA 208
12.1.4 AUSTRALIA 219
12.1.5 SOUTH KOREA 230
12.1.6 SINGAPORE 241
12.1.7 THAILAND 252
12.1.8 PHILIPPINES 263
12.1.9 MALAYSIA 274
12.1.10 INDONESIA 285
12.1.11 VIETNAM 296
12.1.12 TAIWAN 306
12.1.13 REST OF ASIA-PACIFIC 316
13 ASIA-PACIFIC STROKE MARKET, COMPANY LANDSCAPE 317
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 317
14 SWOT ANALYSIS 318
15 COMPANY PROFILES 319
15.1 BRISTOL-MYERS SQUIBB COMPANY 319
15.1.1 COMPANY SNAPSHOT 319
15.1.2 REVENUE ANALYSIS 320
15.1.3 COMPANY SHARE ANALYSIS 320
15.1.4 PRODUCT PORTFOLIO 320
15.2 F. HOFFMANN-LA ROCHE LTD 322
15.2.1 COMPANY SNAPSHOT 322
15.2.2 REVENUE ANALYSIS 323
15.2.3 COMPANY SHARE ANALYSIS 323
15.2.4 PRODUCT PORTFOLIO 324
15.2.5 RECENT DEVELOPMENT 324
15.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 325
15.3.1 COMPANY SNAPSHOT 325
15.3.2 COMPANY SHARE ANALYSIS 325
15.3.3 PRODUCT PORTFOLIO 326
15.3.4 RECENT DEVELOPMENT 327
15.4 DAIICHI SANKYO COMPANY, LIMITED 328
15.4.1 COMPANY SNAPSHOT 328
15.4.2 REVENUE ANALYSIS 328
15.4.3 COMPANY SHARE ANALYSIS 329
15.4.4 PRODUCT PORTFOLIO 329
15.4.5 RECENT DEVELOPMENT 330
15.5 SANOFI 331
15.5.1 COMPANY SNAPSHOT 331
15.5.2 REVENUE ANALYSIS 331
15.5.3 COMPANY SHARE ANALYSIS 332
15.5.4 PRODUCT PORTFOLIO 332
15.6 ABBOTT 333
15.6.1 COMPANY SNAPSHOT 333
15.6.2 REVENUE ANALYSIS 333
15.6.3 PRODUCT PORTFOLIO 334
15.6.4 RECENT DEVELOPMENT 334
15.7 AMNEAL PHARMACEUTICALS LLC 336
15.7.1 COMPANY SNAPSHOT 336
15.7.2 REVENUE ANALYSIS 336
15.7.3 PRODUCT PORTFOLIO 337
15.7.4 RECENT DEVELOPMENT 337
15.8 ASTRAZENECA 338
15.8.1 COMPANY SNAPSHOT 338
15.8.2 REVENUE ANALYSIS 338
15.8.3 PRODUCT PORTFOLIO 339
15.8.4 RECENT DEVELOPMENT 339
15.9 BAYER AG 340
15.9.1 COMPANY SNAPSHOT 340
15.9.2 REVENUE ANALYSIS 341
15.9.3 PRODUCT PORTFOLIO 341
15.9.4 RECENT DEVELOPMENT 342
15.10 FRESENIUS SE & CO. KGAA 344
15.10.1 COMPANY SNAPSHOT 344
15.10.2 REVENUE ANALYSIS 344
15.10.3 PRODUCT PORTFOLIO 345
15.10.4 RECENT DEVELOPMENT 345
15.11 GLENMARK PHARMACEUTICALS LTD. 346
15.11.1 COMPANY SNAPSHOT 346
15.11.2 REVENUE ANALYSIS 347
15.11.3 PRODUCT PORTFOLIO 347
15.11.4 RECENT DEVELOPMENT 348
15.12 JOHNSON & JOHNSON SERVICES, INC. 349
15.12.1 COMPANY SNAPSHOT 349
15.12.2 REVENUE ANALYSIS 349
15.12.3 PRODUCT PORTFOLIO 350
15.12.4 RECENT DEVELOPMENT 350
15.13 LUPIN 351
15.13.1 COMPANY SNAPSHOT 351
15.13.2 REVENUE ANALYSIS 352
15.13.3 PRODUCT PORTFOLIO 352
15.13.4 RECENT DEVELOPMENT 353
15.14 MEDTRONIC 354
15.14.1 COMPANY SNAPSHOT 354
15.14.2 REVENUE ANALYSIS 354
15.14.3 PRODUCT PORTFOLIO 355
15.14.4 RECENT DEVELOPMENT 356
15.15 PENUMBRA, INC. 357
15.15.1 COMPANY SNAPSHOT 357
15.15.2 REVENUE ANALYSIS 358
15.15.3 PRODUCT PORTFOLIO 358
15.15.4 RECENT DEVELOPMENT 359
15.16 PFIZER INC. 360
15.16.1 COMPANY SNAPSHOT 360
15.16.2 REVENUE ANALYSIS 361
15.16.3 PRODUCT PORTFOLIO 362
15.16.4 RECENT DEVELOPMENT 362
15.17 SANDOZ AG 363
15.17.1 COMPANY SNAPSHOT 363
15.17.2 REVENUE ANALYSIS 363
15.17.3 PRODUCT PORTFOLIO 364
15.17.4 RECENT DEVELOPMENT 365
15.18 TEVA PHARMACEUTICALS USA, INC. 366
15.18.1 COMPANY SNAPSHOT 366
15.18.2 REVENUE ANALYSIS 366
15.18.3 PRODUCT PORTFOLIO 367
15.18.4 RECENT DEVELOPMENT 368
15.19 VIATRIS INC. 369
15.19.1 COMPANY SNAPSHOT 369
15.19.2 REVENUE ANALYSIS 369
15.19.3 PRODUCT PORTFOLIO 370
15.19.4 RECENT DEVELOPMENT 371
16 QUESTIONNAIRE 372
17 RELATED REPORTS 375
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security